DK2694544T3 - Monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvej (tfpi) - Google Patents
Monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvej (tfpi) Download PDFInfo
- Publication number
- DK2694544T3 DK2694544T3 DK12762959.0T DK12762959T DK2694544T3 DK 2694544 T3 DK2694544 T3 DK 2694544T3 DK 12762959 T DK12762959 T DK 12762959T DK 2694544 T3 DK2694544 T3 DK 2694544T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- tfpi
- val
- antibody
- thr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (2)
1. Isoleret monoklonalt antistof, der binder til en epitop af human inhibitor af vævsfaktoraktiveringsvej (SEQ ID NO: 1), hvor epitopen omfatter en eller flere rester af Kunitz-domæne 1 valgt fra gruppen, der består af Asp31, Asp32, Gly33, Pro34, Cys35, Lys36, Cys59, Glu60 og Asn62, og hvor epitopen omfatter en eller flere rester af Kunitz-domæne 2 valgt fra gruppen, der består af GlulOO, GlulOl, Prol03, Glyl04, Ilel05, Cysl06, Argl07, Glyl08, Tyrl09, Phell4, Asnll6, Glul23, Argl24, Lysl26, Tyrl27 og Glyl28, og hvor det isolerede monoklonale antistof omfatter en variabel let kæde (Vl) ifølge SEQ ID NO: 4 og en variabel tung kæde (Vh) ifølge SEQ ID NO: 5.
2. Farmaceutisk sammensætning, der omfatter en terapeutisk effektiv mængde af det monoklonale antistof ifølge krav 1 og et farmaceutisk acceptabelt bæremateriale.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471101P | 2011-04-01 | 2011-04-01 | |
| PCT/US2012/031538 WO2012135671A2 (en) | 2011-04-01 | 2012-03-30 | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2694544T3 true DK2694544T3 (da) | 2019-04-15 |
Family
ID=46932389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12762959.0T DK2694544T3 (da) | 2011-04-01 | 2012-03-30 | Monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvej (tfpi) |
Country Status (37)
| Country | Link |
|---|---|
| US (5) | US20140294832A1 (da) |
| EP (1) | EP2694544B1 (da) |
| JP (4) | JP6170903B2 (da) |
| KR (2) | KR20190079698A (da) |
| CN (2) | CN107090046A (da) |
| AU (3) | AU2012236296A1 (da) |
| BR (1) | BR112013025376A2 (da) |
| CA (2) | CA2831907C (da) |
| CL (1) | CL2013002811A1 (da) |
| CO (1) | CO6890074A2 (da) |
| CR (1) | CR20130499A (da) |
| CU (1) | CU20130128A7 (da) |
| CY (1) | CY1121538T1 (da) |
| DK (1) | DK2694544T3 (da) |
| DO (1) | DOP2013000218A (da) |
| EA (2) | EA201991704A3 (da) |
| EC (1) | ECSP13012913A (da) |
| ES (1) | ES2722824T3 (da) |
| GT (1) | GT201300229A (da) |
| HK (1) | HK1243426A1 (da) |
| HR (1) | HRP20190467T1 (da) |
| HU (1) | HUE042706T2 (da) |
| IL (4) | IL228633B (da) |
| LT (1) | LT2694544T (da) |
| MX (1) | MX2013011218A (da) |
| MY (2) | MY190951A (da) |
| PE (1) | PE20141149A1 (da) |
| PH (4) | PH12013502039B1 (da) |
| PL (1) | PL2694544T3 (da) |
| PT (1) | PT2694544T (da) |
| RS (1) | RS58633B1 (da) |
| SG (2) | SG193594A1 (da) |
| SI (1) | SI2694544T1 (da) |
| TR (1) | TR201905101T4 (da) |
| UA (1) | UA113623C2 (da) |
| WO (1) | WO2012135671A2 (da) |
| ZA (1) | ZA201308169B (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2379096T1 (sl) | 2008-12-19 | 2020-03-31 | Baxalta GmbH | Zaviralci TFPI in postopki uporabe |
| RU2562114C2 (ru) | 2008-12-22 | 2015-09-10 | Ново Нордиск А/С | Антитела против ингибитора метаболического пути тканевого фактора |
| KR101903931B1 (ko) | 2010-03-01 | 2018-10-02 | 바이엘 헬스케어 엘엘씨 | 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체 |
| WO2011115712A2 (en) | 2010-03-19 | 2011-09-22 | Baxter International Inc | Tfpi inhibitors and methods of use |
| ES2722824T3 (es) * | 2011-04-01 | 2019-08-19 | Bayer Healthcare Llc | Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) |
| DK2827883T3 (da) | 2012-03-21 | 2019-07-29 | Baxalta GmbH | Tfpi-inhibitorer og fremgangsmåder til anvendelse |
| JP6283017B2 (ja) | 2012-03-30 | 2018-02-21 | バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ | プロテアーゼ制御抗体 |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| JP6586016B2 (ja) * | 2013-03-15 | 2019-10-02 | ノヴォ ノルディスク アー／エス | 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体 |
| CN105452298B (zh) | 2013-03-15 | 2021-08-31 | 拜尔健康护理有限责任公司 | 改善药代动力学的具有跨pH范围差异结合的抗TFPI抗体变体 |
| US10457743B2 (en) | 2013-07-19 | 2019-10-29 | Novo Nordisk A/S | Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity |
| WO2016042093A1 (en) * | 2014-09-17 | 2016-03-24 | Novo Nordisk A/S | Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161) |
| AU2015384281B2 (en) | 2015-02-25 | 2018-11-22 | Mogam Institute For Biomedical Research | Novel antibody binding to TFPI and composition comprising the same |
| MX2018002048A (es) * | 2015-08-19 | 2018-04-13 | Pfizer | Anticuerpos inhibidores de via del factor tisular y usos de los mismos. |
| WO2020021890A1 (ja) * | 2018-07-25 | 2020-01-30 | ソニー株式会社 | 血液凝固系解析装置 |
| CN112442127A (zh) * | 2019-08-29 | 2021-03-05 | 苏州康宁杰瑞生物科技有限公司 | 针对tfpi的单克隆抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06153985A (ja) * | 1992-11-16 | 1994-06-03 | Teijin Ltd | モノクローナル抗体 |
| UA112050C2 (uk) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi) |
| RU2562114C2 (ru) * | 2008-12-22 | 2015-09-10 | Ново Нордиск А/С | Антитела против ингибитора метаболического пути тканевого фактора |
| KR101903931B1 (ko) * | 2010-03-01 | 2018-10-02 | 바이엘 헬스케어 엘엘씨 | 조직 인자 경로 억제제 (ｔｆｐｉ)에 대한 최적화된 모노클로날 항체 |
| ES2722824T3 (es) * | 2011-04-01 | 2019-08-19 | Bayer Healthcare Llc | Anticuerpos monoclonales contra el inhibidor de la ruta del factor tisular (TFPI) |
| US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| US8613919B1 (en) * | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
-
2012
- 2012-03-30 ES ES12762959T patent/ES2722824T3/es active Active
- 2012-03-30 DK DK12762959.0T patent/DK2694544T3/da active
- 2012-03-30 MX MX2013011218A patent/MX2013011218A/es unknown
- 2012-03-30 AU AU2012236296A patent/AU2012236296A1/en not_active Abandoned
- 2012-03-30 PL PL12762959T patent/PL2694544T3/pl unknown
- 2012-03-30 RS RS20190338A patent/RS58633B1/sr unknown
- 2012-03-30 EA EA201991704A patent/EA201991704A3/ru unknown
- 2012-03-30 SG SG2013071477A patent/SG193594A1/en unknown
- 2012-03-30 CN CN201710275470.2A patent/CN107090046A/zh active Pending
- 2012-03-30 EP EP12762959.0A patent/EP2694544B1/en active Active
- 2012-03-30 PE PE2013002137A patent/PE20141149A1/es active IP Right Grant
- 2012-03-30 MY MYPI2017001205A patent/MY190951A/en unknown
- 2012-03-30 KR KR1020197018445A patent/KR20190079698A/ko not_active Application Discontinuation
- 2012-03-30 EA EA201301107A patent/EA034214B1/ru not_active IP Right Cessation
- 2012-03-30 SI SI201231558T patent/SI2694544T1/sl unknown
- 2012-03-30 CA CA2831907A patent/CA2831907C/en not_active Expired - Fee Related
- 2012-03-30 CA CA3068997A patent/CA3068997A1/en not_active Abandoned
- 2012-03-30 MY MYPI2013701814A patent/MY165499A/en unknown
- 2012-03-30 TR TR2019/05101T patent/TR201905101T4/tr unknown
- 2012-03-30 UA UAA201312686A patent/UA113623C2/uk unknown
- 2012-03-30 CN CN201280026938.XA patent/CN103797030B/zh not_active Expired - Fee Related
- 2012-03-30 US US14/009,334 patent/US20140294832A1/en not_active Abandoned
- 2012-03-30 HU HUE12762959A patent/HUE042706T2/hu unknown
- 2012-03-30 PT PT12762959T patent/PT2694544T/pt unknown
- 2012-03-30 LT LTEP12762959.0T patent/LT2694544T/lt unknown
- 2012-03-30 WO PCT/US2012/031538 patent/WO2012135671A2/en active Application Filing
- 2012-03-30 SG SG10201602606UA patent/SG10201602606UA/en unknown
- 2012-03-30 BR BR112013025376A patent/BR112013025376A2/pt active Search and Examination
- 2012-03-30 JP JP2014502846A patent/JP6170903B2/ja not_active Expired - Fee Related
- 2012-03-30 KR KR1020137028821A patent/KR101995302B1/ko active IP Right Grant
-
2013
- 2013-09-27 GT GT201300229A patent/GT201300229A/es unknown
- 2013-09-30 PH PH12013502039A patent/PH12013502039B1/en unknown
- 2013-09-30 CR CR20130499A patent/CR20130499A/es unknown
- 2013-09-30 CU CU2013000128A patent/CU20130128A7/es unknown
- 2013-09-30 CL CL2013002811A patent/CL2013002811A1/es unknown
- 2013-09-30 IL IL228633A patent/IL228633B/en active IP Right Grant
- 2013-09-30 DO DO2013000218A patent/DOP2013000218A/es unknown
- 2013-10-01 CO CO13233113A patent/CO6890074A2/es unknown
- 2013-10-01 EC ECSP13012913 patent/ECSP13012913A/es unknown
- 2013-10-31 ZA ZA2013/08169A patent/ZA201308169B/en unknown
-
2016
- 2016-07-27 US US15/221,104 patent/US20170107298A1/en not_active Abandoned
-
2017
- 2017-02-17 JP JP2017027825A patent/JP6363747B2/ja not_active Expired - Fee Related
- 2017-05-10 AU AU2017203105A patent/AU2017203105A1/en not_active Abandoned
-
2018
- 2018-01-22 US US15/877,349 patent/US20180194857A1/en not_active Abandoned
- 2018-01-25 IL IL257145A patent/IL257145A/en unknown
- 2018-02-22 HK HK18102557.1A patent/HK1243426A1/zh unknown
- 2018-06-28 JP JP2018122610A patent/JP2018172411A/ja active Pending
- 2018-12-27 US US16/234,239 patent/US20190194353A1/en not_active Abandoned
-
2019
- 2019-02-28 PH PH12019500440A patent/PH12019500440A1/en unknown
- 2019-02-28 PH PH12019500439A patent/PH12019500439A1/en unknown
- 2019-02-28 PH PH12019500441A patent/PH12019500441A1/en unknown
- 2019-03-08 HR HRP20190467TT patent/HRP20190467T1/hr unknown
- 2019-03-15 AU AU2019201814A patent/AU2019201814A1/en not_active Abandoned
- 2019-03-22 CY CY20191100343T patent/CY1121538T1/el unknown
-
2020
- 2020-05-14 IL IL274686A patent/IL274686B/en unknown
- 2020-10-20 JP JP2020176145A patent/JP2021019619A/ja not_active Withdrawn
-
2021
- 2021-03-24 US US17/211,631 patent/US20220041752A1/en not_active Abandoned
- 2021-06-09 IL IL283829A patent/IL283829A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2694544T3 (da) | Monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvej (tfpi) | |
| DK2542257T3 (da) | Optimerede monoklonale antistoffer mod vævsfaktorvej-inhibitor (tfpi) | |
| AU2018271420B2 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) | |
| AU2013202745B2 (en) | Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI) | |
| NZ615969B2 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |